title: Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.
abstract: BACKGROUND
  HER-2 amplification is an important prognostic biomarker and treatment determinant in breast carcinoma.
  
  
  OBJECTIVE
  To correlate immunocytochemical (ICC) expression of HER-2 and gene amplification determined by chromogenic in situ hybridisation (CISH) using liquid based cytology (LBC) with immunohistochemistry (IHC) and CISH using histological samples of the same breast carcinomas.
  
  
  METHODS
  Frozen sections and cytobrushings of 103 breast carcinomas were analysed. Four techniques were performed on each tumour: two on LBC samples (ICC, and CISH, both graded as positive, indeterminate, or negative) and two on histological samples (IHC and CISH). Two cell lines (MCF-7, negative; BT 474, positive) were used as controls for cytological analysis. A complementary fluorescence in situ hybridisation technique was carried out in histological samples with low amplification (4-10 dots/nucleus).
  
  
  RESULTS
  Interobserver agreement for the four techniques calculated by the kappa coefficient indicated a substantial agreement. Nine cases failed in cytology because of poor cellularity. Among 94 cases, 19 were amplified; 73, 12, and 9 tumours were scored 0 or 1+, 2+, and 3+, respectively by IHC and 75, 13, and 6, respectively, by ICC. CISH found no amplification in 72 tumours. Correlations between the IHC and CISH results in the histological and cytological samples were always significant.
  
  
  CONCLUSIONS
  Her-2 status could be determined in LBC samples and correlated well with reference histological methods using in situ hybridisation. ICC was less reliable because of the presence of the cytoplasmic membrane. However, these results should be confirmed by a large multicentre study.
authors.affiliation: Laboratoire Pol Bouin, Centre Hospitalier et Universitaire de Reims, 45, Rue Cognacq-Jay, 51092 Reims Cedex, France. hsartelet@chu-reims.fr
authors.forename: H
authors.initials: H
authors.lastname: Sartelet
authors.forename: E
authors.initials: E
authors.lastname: Lagonotte
authors.forename: M
authors.initials: M
authors.lastname: Lorenzato
authors.forename: I
authors.initials: I
authors.lastname: Duval
authors.forename: C
authors.initials: C
authors.lastname: Lechki
authors.forename: C
authors.initials: C
authors.lastname: Rigaud
authors.forename: J
authors.initials: J
authors.lastname: Cucherousset
authors.forename: A
authors.initials: A
authors.lastname: Durlach
authors.forename: O
authors.initials: O
authors.lastname: Graesslin
authors.forename: P
authors.initials: P
authors.lastname: Abboud
authors.forename: M
authors.initials: M
authors.lastname: Doco-Fenzy
authors.forename: C
authors.initials: C
authors.lastname: Quereux
authors.forename: B
authors.initials: B
authors.lastname: Costa
authors.forename: M
authors.initials: M
authors.lastname: Polette
authors.forename: J-N
authors.initials: JN
authors.lastname: Munck
authors.forename: P
authors.initials: P
authors.lastname: Birembaut
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D044584:Carcinoma, Ductal / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D007124:Immunoenzyme Techniques; D017403:In Situ Hybridization; D017404:In Situ Hybridization, Fluorescence; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism; D011379:Prognosis; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases